ACT 001

Drug Profile

ACT 001

Alternative Names: ACT001

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Accendatech
  • Class Antineoplastics
  • Mechanism of Action NF-kappa B inhibitors; STAT3 transcription factor inhibitors; Thyroid hormone binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma; Solid tumours

Most Recent Events

  • 01 Jun 2018 Interim efficacy, adverse events and pharmacokinetics data from a Phase-I trial in Solid tumours presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 06 Feb 2018 Chemical structure information added
  • 01 Dec 2017 ACT 001 is available for licensing as of 01 Dec 2017. http://accendatech.com/en/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top